Skip to main content
FDA orphan status granted to Abeona's infantile Batten disease drug

The FDA gave orphan drug designation to Abeona Therapeutics' ABO-202, which is being developed as a treatment for infantile Batten disease. The company expects to launch clinical trials of the drug candidate this year.

Full Story: